EU Greenlights €400m in Aid for Sanofi Insulin Plant in Germany
13 Articles
13 Articles
The European Commission authorises Germany to subsidise the Sanofi pharmaceutical group. The aim is to maintain the group's activity in Europe, in order to secure the European supply of insulin. To guarantee access to this essential medicine in the treatment of diabetes, Berlin releases EUR 400 million.
Here you can find information on the topic "Medicine". Read now "EU approves millions of Sanofi insulin factory in Hesse".
The pharmaceutical company Sanofi is building a new production plant for insulin in Frankfurt. He needs support for this – Germany can now provide it.
The EU Commission has approved aid for a billion-dollar investment in Frankfurt. There is now nothing in the way of the construction of the new Sanofi production facility.
The European Commission has approved €400 million in state aid for insulin manufacturer Sanofi. The company is expected to build a new plant and produce over a ton of the drug within the next few years, reports Rynek Zdrowia.
The European Commission has approved a €400 million German state aid program for Sanofi. The program will help the company maintain and expand its insulin production in Germany and secure supplies of the substances needed for its production. The goal is to increase the security of insulin supply for patients in Germany and Europe.
Coverage Details
Bias Distribution
- 75% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
